Primary tumour

\[ N = 425 \]

No lymph node metastasis

\[ N = 128 \]

Lymph node metastases,

\[ N = 297 \]

Primary tumour

Tissue available

\[ N = 425 \]

Lymph node metastases

Tissue available

\[ N = 273 \]

**ER** analysis in primary tumour and corresponding lymph node assessed

\[ N = 262 \]

**PR** analysis in primary tumour and corresponding lymph node assessed

\[ N = 257 \]

TMA constructed for primary tumour, \( N = 425 \) and lymph node metastasis, \( N = 273 \), for further analysis of Ki67 and HER2

**Ki67** analysis in primary tumour and corresponding lymph node assessed

\[ N = 101 \]

**HER2** analysis in primary tumour and corresponding lymph node assessed

\[ N = 104 \]

Available for assessment of molecular subgroup by combining ER, PR, Ki67 and HER2 in primary tumor and corresponding lymph node

\[ N = 85 \]